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Loci discovered by genome-wide association studies (GWAS) predominantly map outside protein-coding 
genes. The interpretation of the functional consequences of non-coding variants can be greatly enhanced by 
catalogues of regulatory genomic regions in cell lines and primary tissues. However, robust and readily 
applicable methods to systematically evaluate the contribution of these regions to genetic variation 
implicated in diseases or quantitative traits are still lacking. Here we propose a novel approach that 
leverages GWAS findings with regulatory or functional annotations to classify features relevant to a 
phenotype of interest. Within our framework, we account for major sources of confounding that current 
methods do not offer. We further assess enrichment for 29 GWAS traits within ENCODE and Roadmap 
derived regulatory regions. We characterize unique enrichment patterns for traits and annotations, driving 
novel biological insights. The method is implemented in standalone software and an R package to facilitate 
its application by the research community. 
  
Introduction 
  
Genome-wide association studies (GWAS) in humans have discovered susceptibility variants for complex 
diseases and biomedical quantitative traits, with over 75,000 associations found to date 1,2, representing a 
large investment in resources, time and organization by the worldwide research community. The majority 
(~90%) of implicated variants are classified as intronic or intergenic 3 and thus cannot be readily assigned to an 
underlying cellular or molecular mechanism. This has prompted a number of efforts to annotate the putative 
functional consequences of variants in cell-specific contexts from experimentally derived regulatory regions 
(e.g. regions marked by histone modifications, transcription factor binding 3–6), principally as a means to inform 
and accelerate functional validation. 
  
The robust identification of the combinations of annotations for these regulatory regions (henceforth referred 
to generically as ‘regulatory annotations’) and cell types that are biologically most informative for a given 
disease or quantitative trait of interest (henceforth referred generically to as 'phenotype') requires that one 
can confidently distinguish correlations driven by biology from those arising by chance. Regulatory annotations 
may cover a large proportion of the genome, and thus many disease-associated variants will map within them 
by chance. In addition, the heterogeneous distribution of genetic variants and functional regions in the 
genome may result in their non-random association with genomic features such as genes 7,8, which in turn may 
drive spurious correlations that confound correct interpretation of these correlation patterns. 
  
Functional enrichment methods assess the relative contribution of regulatory annotations to a phenotype of 
interest. In their simplest implementation, they estimate enrichment of association p-values (or z-scores) 
based on comparisons of the full set of genome-wide association (GWA) variants 9–13, or on subsets of highly 
associated variants (e.g. genome-wide significant variants) 14–16. These approaches have identified many 
biologically plausible patterns of enrichment and can be broadly used for ranking the relative contribution of 
features. For instance, variants associated with lipid traits and Crohn’s disease are enriched in open chromatin 
derived from liver and immune cells, respectively 13, reflecting biological functions. However, there is currently 
little confidence in interpreting unexpected enrichments, because of various statistical concerns. First, overly 
simplistic models that do not account for known confounders such as local linkage disequilibrium (LD) and 
local gene density can lead to spurious enrichment patterns 14.  Second, tests based on subsets of variants 
typically probe a limited number of genomic features, whereas evidence of enrichment occurs well below 
genome-wide significance 11,12. Due to the large number of annotations now available, a third problem has 
emerged of prioritizing the most informative set from a large number of often correlated functional 
annotations. Methodological improvements are thus needed to increase the accuracy of inference, and to 
realize the full potential of those costly experiments in focused analysis.  
  
Here we present a novel statistical approach that leverages GWAS findings with functional (i.e. regulatory or 
protein-coding) annotations to find features relevant to a phenotype of interest. This method accounts for LD, 
matched genotyping variants and local gene density with the application of logistic regression to derive 
statistical significance. We name our method GARFIELD, which stands for GWAS Analysis of Regulatory or 
Functional Information Enrichment with LD correction. We use GARFIELD to analyze the enrichment patterns 
of publicly available GWAS summary statistics using regulatory maps from the ENCODE 3 and Roadmap 
Epigenomics 5 projects.  We describe expected and novel enrichments that illustrate the molecular and cellular 
basis of well-studied traits, which we expect to help drive novel biological insights and enhance efforts to 
prioritize variants for focused functional exploration. Finally, we developed new software to facilitate the 
application of our approach by the research community, and tools for effective visualization of enrichment 
results that scale to thousands of potential functional elements.  
 
Results 
  
Method Overview 
  
The analysis workflow implemented in GARFIELD is summarized in Figure 1 and Online Methods. The method 
requires four inputs: (i) a set of genome-wide genetic variant association p-values with a phenotype of 
interest; (ii) genome-wide genomic coordinates for regulatory annotations of interest; (iii) lists of LD tags for 
each variant (r2 ≥ 0.01 and r2 ≥ 0.8 within 1-MB windows) from a reference population of interest (e.g. 
Caucasian) and (iv) the distance of each variant to the nearest transcription start site (TSS). Given these inputs, 
the method first uses a greedy procedure to extract a set of independent variants from the genome-wide 
genetic variants, using LD (r2 ≥ 0.01) and distance information (‘LD pruning step’). Second, it annotates each 
variant with a regulatory annotation if either the variant, or a correlated variant (r2 ≥ 0.8), overlaps the feature 
(‘LD tagging annotation step’). Third, it calculates odds ratios (OR) and enrichment p-values at different GWAS 
p-value thresholds (denoted as ‘T’) for each annotation using a logistic regression model with ‘feature 
matching’ (Online Methods) on variants by distance to the nearest TSS and number of LD proxies (r2 ≥ 0.8) 
(used as categorical covariates). This pruning strategy is conservative, as a potential loss of the true causal 
variant at a small fraction of the loci due to pruning will be offset by the analysis of genome-wide enrichment 
patterns. We thus believe this is a conservative but sound approach for identifying annotations that harbor 
more GWAS variants (at a given threshold T) than expected by chance. To correct for multiple testing on the 
number of different annotations, we further estimate the effective number of independent annotations by 
using the eigenvalues of the correlation matrix of the binary annotation overlap matrix from Figure 1 (adapted 
from Galwey et al. 17) (Online Methods) and then apply a Bonferroni correction at the 95% significance level. 
This takes into account the tissue-selective components of regulatory data, namely that closely related cell 
types and tissues are more similar to each other than different ones. Our single annotation approach can be 
viewed as an extension of Maurano et al. 11 (see also Supplementary Table 1) with two critical improvements. 
First, we account for the effect of local variant correlations by restricting enrichment calculations to sets of 
independent variants (LD pruning step). Second, we employ a testing procedure that accounts for systematic 
differences in gene distance and number of proxies in the variant set. 
 
Additionally, we implement a heuristic procedure to combine the biological signal contained in correlated 
annotations, which allows us to identify conditionally independent sets of regulatory annotations 
underpinning the enrichment signals. To reduce the computational burden of searching through all possible 
combinations of available annotations, we first obtain enrichment p-values for all annotations separately, 
using the default single-annotation GARFIELD model. We then rank all statistically significant annotations by 
their enrichment p-value and iteratively add each such annotation to the model if it significantly improves the 
model fit compared to the model not including the annotation (analysis of deviance using a chi-squared test).  
 
We compared GARFIELD to five widely used alternative methods (LDSC 10, fgwas 13, GoShifter 14, GREGOR 16 
and GPA 9), while noting that benchmarking of methods is typically best done by investigators independent of 
the method developers. To estimate the false positive rate (FPR), we used 21 real disease or quantitative trait 
GWASs with the required summary statistics for all methods and greater than five independent genetic 
variants at the T < 10-8 threshold (Online Methods). We assessed the enrichment of each trait against 1,000 
peak region annotations, simulated to match observed peak lengths and between peak distances for DNaseI 
hypersensitive sites (DHS) in HepG2 cells (ENCODE). We compared GARFIELD to the five alternative methods 
and to a naive model, where enrichment ORs are calculated without accounting for LD or other features. FPRs 
were estimated by the observed proportion of significantly enriched annotations per phenotype (Online 
Methods). At the 5% significance level, methods not modelling LD produced significantly inflated FPRs (0.15 
and 0.33 on average for Naïve and GPA, respectively) (Figure 2a). GARFIELD, fgwas, LDSC and GoShifter 
preserved the FPR for all traits, while GREGOR yielded more false positive results than expected (average FPR 
0.09). Further assessment of GARFIELD for a set of 29 traits showed that FPRs are also preserved when 
lowering the threshold from T < 10-8 to T < 10-5 (Supplementary Figure 1a). 
  
To assess the value of feature matching in significance testing, we employed GARFIELD with and without 
feature correction to 424 open chromatin annotations in 29 phenotypes at the T < 10-8 threshold. As expected, 
we found that feature matching controls for biases in enrichment analysis by significantly reducing the number 
of observed enrichments (Wilcoxon signed rank test proportion median = 0.46, p-value = 1.4 × 10-4) (Figure 
2b). We further explored the relative contribution of each feature by comparing the number of significant 
enrichments detected in a feature-corrected model compared to the uncorrected model. We found median 
proportion reduction estimates of enrichments of 0.34 (p-value = 1.4 × 10-4) and 0.10 (p-value = 1.1 × 10-3) for 
the number of LD proxies and TSS distance, respectively (Supplementary Figure 1b-c). Estimates were 
concordant between GWAS p-value thresholds (Supplementary Figure 1d). These tests suggest that LD proxy 
number is the single most important confounder, although not sufficient to correct for individually when 
compared to the model correcting for both features together.  
 
Enrichment in open chromatin regions 
  
To assess the relative enrichment of phenotype-genotype associations in different cell types, we first applied 
GARFIELD to a generic regulatory annotation denoting open chromatin (DNaseI hypersensitive sites) in 424 cell 
lines and primary cell types from ENCODE 3 and Roadmap Epigenomics 5 (Supplementary Table 2). We 
considered five diseases and 24 quantitative traits with publicly available GWAS summary statistics. For each 
trait-annotation pair we derived enrichment estimates at eight GWAS P-value thresholds (T < 10-1 to T < 10-8). 
At the most stringent cut-off (T < 10-8), there were a median of 21 independent variants per trait after LD 
pruning (range 0-117, Table 1 and Supplementary Table 3), while at a more permissive threshold (T < 10-5) 
there were a median of 76 variants per trait (range 11-619).  
 
We found statistically significant enrichments (p < 2.6 × 10-4; Online methods, Supplementary Note) for the 
majority of traits considered, highlighting clear differences in enrichment patterns between traits 
(Supplementary Table 4). As clearly visible from enrichment wheel plots, some traits displayed relatively 
ubiquitous enrichment (e.g. height, Figure 3a), while others showed relatively narrow enrichment (e.g. 
ulcerative colitis, Figure 3b, see also Supplementary Figure 2). Blood cells were overall the most enriched 
tissue type in hematological traits and autoimmune diseases, but provided little to no enrichment for glycemic, 
blood pressure and anthropometric traits (except height which was enriched in nearly all tissues). As 
predicted, incorporating sub-threshold associations (T < 10-5) increased the resolution of enrichment patterns 
across traits (Table 1). For instance, at T < 10-8 there were no annotations enriched for waist-to-hip ratio 
(WHR), while at T < 10-5 there were 19 significant enrichments, 18 of which coming from muscle or fetal 
muscle tissue. For HbA1C and fasting glucose again there were no enrichments at T < 10-8, while at T < 10-5 we 
uncovered links to blood, fetal stomach and fetal intestine tissues. Additionally, for low density lipoprotein 
(LDL) cholesterol we found a single enrichment in colon at T < 10-8, while the permissive threshold allowed us 
to detect much larger number of relevant annotations (75), including liver, blood and fetal intestine cell types. 
Overall, 89% of the enrichments at the T < 10-8 threshold were also identified at T < 10-5 (between-threshold 
log10 enrichment p-value correlation = 0.85) (Supplementary Figure 3) showing high degree of agreement 
between thresholds. 
  
The observed enrichments reflect current understanding of key cellular types for disease, augmented with 
novel observations. In the former category were enrichments of lipid traits in blood, liver, fetal intestine and 
fetal thymus cell types; of hematological traits in blood, and of autoimmune diseases (ulcerative colitis, 
Crohn’s disease, inflammatory bowel disease (IBD)) in blood and fetal intestine 11,13,18. Potentially interesting 
examples of the latter category include the enrichment of Caco-2 (a well-established gut epithelia cellular 
model) elements for LDL cholesterol, the enrichment of (fetal) muscle and placenta cell type elements in high 
density lipoprotein (HDL) cholesterol and foetal intestine in Hemoglobin (HGB). For each trait, we also 
employed GARFIELD’s heuristic multiple annotation approach illustrated earlier to further prioritize a 
parsimonious set of non-correlated cell types from those with significant enrichment. Only a small proportion 
of enriched annotations detected under univariate settings were retained in the multiple annotation model 
(proportion median = 17%, range 2-100%; median number of annotations retained = 2, range 1-8; Table 1 and 
Supplementary Figure 4). For instance, in height we narrow down the annotations from 364 to 7 (2%). These 
findings are suggestive of a high degree in redundancy between annotations, while also highlighting that in the 
majority of cases biological enrichments are driven by more than a single annotation. For instance, for HDL 
cholesterol we obtain conditionally independent signals coming from blood and liver cell types. 
 
Next, we sought to evaluate GARFIELD against alternative enrichment methods when considering empirical 
phenotypes and DHS data. We performed enrichment analysis for each of the 21 traits from the simulation 
study in each of the 424 cell types using each of the five methods (GARFIELD, GoShifter, fgwas, GREGOR and 
LDSC) shown previously to preserve (or nearly preserve) FPR in simulations (Online Methods; Supplementary 
Table 5). GREGOR yielded the largest number of enrichments (median = 24, max = 398), followed by GARFIELD 
(median = 10, max = 364). Fgwas and LDSC yielded intermediate levels of enrichment (median = 5, max = 327; 
median = 5, max = 144, respectively), while GoShifter was very conservative (median = 0, max = 5). 
Stratification of the enrichments to groups according to the number of methods supporting them further 
showed that GREGOR identified the largest number of enrichments found by at least one other method. 
GARFIELD closely followed GREGOR, whereas fgwas, LDSC and GoShifter showed much lower between-method 
concordance rates. GREGOR also identified the largest number of method-specific enrichments, however, the 
inflated FPR indicates that more enrichments are discovered at the cost of also reporting more false positives, 
making utility of GREGOR alone less desirable in practice (Figure 4a). In the absence of a truth set, the 
observation that GARFIELD captures a large proportion of enrichments consistent with other methods, while 
preserving the FPR, provides an indirect assessment of the robustness of our approach. Overall, enrichments 
of blood cell traits with blood cell regulatory annotations tended to be highly consistent between most 
methods (supported by GARFIELD for 7 traits; GREGOR in 8; fgwas and LDSC in 5 and GoShifter in 1; Figure 4b), 
as expected given their clear biological relevance. Likewise, we observed highly consistent results for height in 
the majority of cell types; schizophrenia (SCZ) in blood and fetal brain; HDL cholesterol in liver, blood and fetal 
placenta (supported by GARFIELD, GREGOR and fgwas); triglycerides in blood (GARFIELD, GREGOR, fgwas and 
LDSC); mean corpuscular volume (MCV) in fetal stomach, fetal spleen and fetal thymus, mean corpuscular 
hemoglobin (MCH) in fetal intestine, fetal stomach and fetal spleen, all of which were supported by at least 
three methods.  
 
Finally, we compared the average CPU time used per method, trait and annotation based on the analysis of 21 
traits and 424 annotations. GARFIELD was faster than all other methods with an average of 0.64 mins needed, 
compared to 2.32 mins for GoShifter, 6.70 mins for LDSC, 16 mins for fgwas and 0.96 mins for GREGOR (Online 
Methods). It has to be noted however that LDSC is fast to run but had a substantial computational burden of 
generating the necessary input files for our custom data (Supplementary Table 6). 
 
Enrichment in promoter and enhancer marks 
 
In light of the current knowledge of relevant links between cell types and complex traits based on promoter 
and enhancer activity, we also sought to evaluate GARFIELD against alternative enrichment methods when 
considering empirical phenotypes and marks of active enhancer (H3K27ac) and active promoter (H3K4me3) 
activity in 127 cell types, similarly to DHS comparisons presented earlier. 
 
We found statistically significant enrichments (p < 5 × 10-4; Online methods) that confirm known biology for 
both H3K27ac and H3K4me3 (Supplementary Table 5). Namely, height was enriched in the majority of tissues 
for both regulatory marks; SCZ showed predominantly enriched in central nervous system (CNS) tissue; blood 
cell traits were enriched in HSC/Blood/Immune cell types and lipids traits in liver tissues for both marks. 
Overall results also show fewer and more specific enrichments in H3K27ac in comparison to H3K4me3 (mean 
17, range [0-72]; and mean 20, range [0-106] number of enrichments, respectively) consistent with higher cell 
type specificity found in active enhancers versus active promoter regions. 
 
Enrichment in genomic segmentations 
  
We additionally sought to compare the relative enrichment of different types of functional genomic marks, 
using ChromHMM 15 data on genomic segmentations for 127 cell types (Supplementary Table 7). For each 
segmentation state and cell type, we analyzed our 29 phenotypes at two different GWAS p-value thresholds (T 
< 10-5 and T < 10-8). Overall, when considering only significantly enriched trait-annotation pairs (p < 3.3 × 10-5; 
Supplementary Table 8), we found higher levels of enrichment for promoters (median OR = 3.4, range [2.0-
10.9] for T < 10-5) and enhancers (median OR = 3.8, range [1.9-68.0]) compared to transcribed regions (median 
OR = 2.6, range [1.8-13.8]), and depletion in quiescent regions (Figure 5a) (similar patterns were obtained for T 
< 10-8, Supplementary Figure 5). Given that transcriptional states mainly mark active genes, it is unsurprising to 
see the contrast of enrichment in transcriptional regions compared to the depletion in quiescent regions. 
Interestingly the enhancer states consistently had stronger enrichments than transcribed regions, an 
observation in agreement with enrichments of hematological traits in cell-matched regulatory states from the 
BLUEPRINT project 19. To confirm these patterns, while controlling for the effect of annotation density on the 
number of enrichments found, we sought to compare only ORs for cell types enriched in both transcribed and 
enhancer pair states (and promoter and transcribed states). Similarly to our previous observations, results 
showed on average greater ORs for enrichment for enhancers when compared to transcribed regions (Figure 
5b) (with a similar but weaker effect for promoters), which provides further evidence that our observation is 
not due to difference in power for enrichment detection between annotations of different density but due to 
their biological relevance to the studied traits. 
 
When considering cell-type specificity, again the trait height was the most ubiquitously enriched phenotype. In 
general, we found the largest ORs for anthropometric traits in active enhancers in adipose and skeletal muscle 
tissues; glycemic traits in active enhancers in pancreatic islets, poised promoters in pancreatic islets and 
stomach mucosa and transcription regulation in blood; lipid traits in active enhancers in liver, transcription 
enhancers in blood and fetal intestine tissue; autoimmune diseases and blood traits in active enhancers in 
tissues including blood and thymus; psychiatric disorder in transcription and bivalent promoters in fetal brain. 
As expected, incorporating sub-threshold associations again greatly increased the resolution of enrichment 
patterns across different traits (Table 1). For example, we found no significant enrichment at T < 10-8 for the 
glycemic indices β-cell activity index (HOMA-B), glycated hemoglobin (HbA1C) and fasting glucose (FG), 
whereas at T < 10-5 HOMA-B was predominantly enriched in active enhancers in pancreatic islets and ES-I3 
cells, HbA1C in active enhancers in psoas muscle and fasting glucose in poised promoters in pancreatic islets 
and stomach mucosa. 
  
Finally, we assessed the extent to which traits shared significantly enriched annotations, by comparing the 
number of cell types per segmentation state that were found to be significantly enriched (or depleted) for a 
single trait compared to multiple traits (Figure 5c and Supplementary Figure 5). Our results confirmed patterns 
of higher cell type specificity for enhancer states, with a median of 67% of cell types in enhancer states that 
were unique to a single trait compared to only 45% for promoter regions at T<10-5 (76% and 50% at T<10-8, 
respectively). This confirms enhancer states as prime regions of interest 19 when seeking to investigate gene 
function underlying complex trait and disease associations.    
  
Software implementation 
  
Many GWA studies seek to explore functional enrichment patterns, but often rely on customized, in-house 
pipelines.  We implemented GARFIELD as a standalone tool in C++ in order to facilitate use by the research 
community (Online Methods). The software allows for enrichment analysis of any user-provided trait with 
variant GWAS p-values and GRCh37 genomic coordinates. We provide over 1000 GENCODE 20, ENCODE 3 and 
Roadmap Epigenomics 5 pre-compiled annotations, UK10K sequence LD data and TSS distance information for 
a ready to use package. Furthermore, custom annotation data can be easily accommodated when provided in 
a simple bed format. In addition, we have also developed a Bioconductor package for the R statistical 
framework to further increase usability. 
  
Discussion 
  
Large-scale efforts 3–6 have been devoted to systematically mapping molecular traits associated with genomic 
regulatory regions. They have greatly enhanced the annotation of putative functional consequences of non-
coding variants in cell-specific contexts, and have further shown to provide links to disease association. 
However, current methods that aim to evaluate the contribution of such regions to genetic variation in disease 
cannot always do so robustly or are not readily applicable for systematic analysis and comparison of broad sets 
of features. In particular, it has been shown that LD and gene density can confound enrichment analysis results 
14. Here we further estimated the relative effect of each of those features and identified LD as the largest 
confounder. Additionally, because of their design, different genotyping platforms (and imputation strategies) 
can create different biases (e.g. number of variants, genomic location distribution). GARFIELD accounts for all 
those features, by obtaining independent signals, expansion to relevant annotations using a population scale 
LD reference and feature matching, and to the best of our knowledge there is no other method that can do so 
without making extremely restrictive assumptions (e.g. Pickrell et al. 13 assume at most one causal variant at a 
given genomic region). Furthermore, many available approaches use variants that reach genome-wide 
significance from association analysis (T < 5 × 10-8) although there has been evidence of enrichment occurring 
well below that level 11,12. To capture these effects, GARFIELD allows for parallel enrichment analyses at 
multiple p-value sub-thresholds, which improves power to detect statistically significant enrichment patterns 
by increasing the number of variants tested, thus enabling its application to traits with underpowered GWA 
studies. Finally, we provide a flexible software platform with effective visualization to enable researchers to 
carry out simultaneous enrichment analysis for thousands of annotations at multiple association thresholds. 
 
In our own application of GARFIELD on existing GWAS and functional datasets we identified a broad set of 
largely expected or previously identified enrichments, for example lipids traits in open chromatin in liver, 
hematological traits in blood and anthropometric traits in active enhancers in adipose tissue. A number of 
GWAS hits do not show significant enrichments even with established cell types when using higher thresholds, 
but GARFIELD’s stepwise, stratified approach uncovers these more nuanced enrichments, shown in the case of 
pancreatic islets with fasting HOMA-B. By analyzing large-scale genome segmentation data, we assessed the 
relative contribution of each segmentation state to the phenotypic traits. We discovered a larger number of 
enrichments coming from transcription states as opposed to promoter and enhancer states together with a 
larger number of shared cell types between traits. These findings may be biologically relevant, or could also be 
a result of statistically larger power for enrichment detection for broader region annotations. Here we show 
that study power differences are not responsible for larger OR values for significant enrichments in promoter 
and enhancer regions when compared to transcribed regions, highlighting them as much more relevant for 
trait associated variants. 
 
Robust, usable and modular methods are critical in the modern large-scale analysis arena, where we expect 
many discoveries to come from principled combinations of heterogeneous datasets. In our hands, GARFIELD 
provided the greatest number of enrichments on real data among methods with full control of FPR in 
simulated data and was among the fastest methods. However, we acknowledge that as authors of this method 
we are not the right group to provide unbiased benchmarking of these methods and look forward to 
independent analysis of these methods. We have already deployed GARFIELD in a number of association study 
settings both in house and more broadly in the community. Our aim in developing it has been to provide the 
most robust statistical framework for analyzing functional enrichments coupled with practical ease of use and 
visualization, and we hope the community will continue to exploit this tool to provide more insights into 
disease mechanisms. 
  
URLs 
Association Summary Statistics 
http://www.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium GIANT BMI 21, height 22 and 
waist hip ratio adjusted for BMI 23 
http://www.magicinvestigators.org/downloads MAGIC BMI adjusted 2hr glucose 24, HOMA B, HOMA IR, fasting 
glucose, fasting insulin 25, fasting proinsulin 26 and HbA1C 27 
http://www.sph.umich.edu/csg/abecasis/public/lipids2010/ Global lipid GWAS summary statistics for LDL, 
HDL, TC and TG 28  
http://www.ibdgenetics.org/downloads.html IIBDGC data on Crohn’s disease, ulcerative colitis and 
Inflammatory Bowel Disease 29 
http://www.georgehretlab.org/icbp_088023401234-9812599.html ICBP data on SBP and DBP 30  
http://diagram-consortium.org/downloads.html DIAGRAM Type 2 diabetes 31 GWAS summary statistics 
http://www.med.unc.edu/pgc/ PGC data on Schizophrenia. 
 
 
DHS data 
http://genome.ucsc.edu/cgi-
bin/hgTrackUi?db=hg19&g=hub_4607_uniformDnase&hubUrl=http://ftp.ebi.ac.uk/pub/databases/ensembl/e
ncode/integration_data_jan2011/hub.txt ENCODE DNaseI hypersensitive sites 
http://www.genboree.org/EdaccData/Current-Release/experiment-sample/Chromatin_Accessibility/ NIH 
Roadmap Epigenomics Mapping  
 
H3K27ac, H3K4me3 and epigenome segmentation data 
http://egg2.wustl.edu/roadmap/web_portal/ Processed NarrowPeak consolidated epigenome data and 25 
state chromatin state model on imputed data for 12 marks. 
 
Software 
http://www.ebi.ac.uk/birney-srv/GARFIELD/ GARFIELD standalone tool; Code availability 
http://bioconductor.org/packages/release/bioc/html/garfield.html/ GARFIELD R-package 
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Figure Legends 
  
Figure 1. Outline of the GARFIELD method. Top panel: three inputs (annotation, p-value and linkage 
disequilibrium (LD) data) are used for the first two analytical steps (LD pruning and variant functional 
annotation), which result in a binary annotation overlap matrix of V pruned variants and A annotations. Middle 
panel: a logistic regression approach is used for testing for enrichment at a GWAS significance P-value 
threshold T while controlling for confounding features such as TSS distance and number of LD proxies. Bottom 
panel: model selection procedure for multiple annotations.  
 
Figure 2. Method assessment. (a) Estimated false positive rate (FPR) from 21 publicly available disease or 
quantitative traits and n = 1,000 simulated independent annotations. The black horizontal line denotes the 5% 
FPR threshold. Error bars denote standard errors. (b) Comparison between the proportion of significant 
annotations (GARFIELD enrichment p-value < 2.6 × 10-4 for multiple testing correction) found from models 
accounting for number of proxies (N) and distance to nearest TSS (T) respectively (x-axis), to a model not 
accounting for any feature (y-axis), for each of 29 publicly available GWA studies and n = 424 DNaseI 
hypersensitive site annotations. Key of trait name labels is shown in Supplementary Table 3. 
  
Figure 3. Enrichment of genome-wide association analysis p-values in DNaseI hypersensitive sites (hotspots).  
(a) Height (HGT) (n = 2,468,982 GWAS variants). (b) Ulcerative colitis (UC) (n = 11,113,952 GWAS variants). 
Radial lines show odds ratio values at eight GWAS P-value thresholds (T) for all ENCODE and Roadmap 
Epigenomics DHS cell lines, sorted by tissue on the outer circle. Dots in the inner ring of the outer circle denote 
significant GARFIELD enrichment (if present) at T < 10-5 (outermost) to T < 10-8 (innermost) after multiple 
testing correction for the number of effective annotations and are coloured with respect to the tissue of the 
cell type they test. Font size of tissue labels reflects the number of cell types from that tissue. Crohn’s disease 
shows predominant enrichment in blood, fetal thymus and fetal intestine tissues whereas height exhibits an 
overall enrichment. OR, odd’s ratio.  
  
Figure 4. Method comparison for 21 GWAS datasets in DNaseI hypersensitive sites (hotspots) and histone 
modifications (H3K27ac and H3K4me3) at the T < 10-8 GWAS significance threshold. (a) Proportion of 
enriched cell types in DNaseI hypersensitive sites identified by each method, where enrichments are stratified 
by the number of methods that support them. GARFIELD, fgwas and LDSC are restricted to positive 
enrichments only so as to be comparable to GREGOR and GoShifter. (b) Summary of significant enrichments 
per tissue and per method for DNaseI hypersensitive data. A colored box is present if the corresponding 
method has found at least one significantly enriched cell type for that tissue after multiple testing correction. 
Colors correspond to the different methods and are the same as in panel a. A grey box denotes that the 
enrichment did not reach significance. Additionally, the size of each box represents the relative magnitude of 
the enrichment. Since each method uses a different enrichment statistic, we have scaled each of them 
separately per method and per trait (e.g. for GARFIELD we scaled the ORs for all cell types for HDL so that 1 
denotes the cell type with the highest enrichment found and 0 the lowest one). (c) Summary of significant 
enrichments per tissue and per method for H3K27ac data. (d) Summary of significant enrichments per tissue 
and per method for H3K4me3 data. (b-d) Sample sizes n per trait (and trait name labels) can be found in 
Supplementary Table 3 denoted by the number of variants in each GWAS study. 
  
Figure 5. Enrichment levels (log OR) and extent of sharing between traits for 25-state chromatin 
segmentations of the NIH Roadmap and ENCODE projects at the T < 10-5 GWAS significance threshold. (a) 
Distribution of significant (log) OR values across the 29 traits considered, split by segmentation state and 
coloured to highlight predicted functional elements (Supplementary Table 9). Number of points n is shown on 
the x-axis below each category. (b) Distribution of the pairwise difference between ORs from all enhancer, 
promoter and transcriptional enhancers and transcriptional regulatory states tested (‘state 1’) to ORs from 
transcription states for significant enrichments only (‘state 2’; e.g. measuring ORc,tEnhA1-ORc,tTx for all cell types c 
and traits t for which p-valuec,tEnhA1 and p-valuec,tTx are both significant). Number of points n is shown on the x-
axis below each category. Boxplots show the median (center line); upper and lower quartiles (box limits), 
whiskers, furthest away point less than l.5x interquartile range (whiskers); points in the distribution( grey 
points) and outliers (black points). (c) Sharing of significantly enriched (or depleted) annotations (n=127 cell 
types) across 27 phenotypes (excluding Crohn’s disease (CD) and Ulcerative colitis (UC) as categories of IBD). 
The barplot displays the number of cell types where an annotation is uniquely enriched/depleted in a trait or 
shared between traits. 
 
Table Legend 
 
Table 1. Summary of GARFIELD enrichment analyses in DNaseI hypersensitive sites, histone modifications 
and genomic segmentations per phenotype. 
Columns denote (A) phenotype category and (B) its index, (C) trait full name and (D) abbreviation, (E) total 
number of variants after LD pruning, (F) number of independent SNPs at GWAS p-value threshold 10-8, (G) 
number of enriched cell types in open chromatin marks at GWAS p-value threshold 10-8, (H) number of 
conditionally independent cell types in open chromatin marks at GWAS p-value threshold 10-8, (I) number of 
enriched cell types in H3K27ac at GWAS p-value threshold 10-8, (J) number of enriched cell types in H3K4me3 
at GWAS p-value threshold 10-8, (K) number of enriched cell types/segmentation states at GWAS p-value 
threshold 10-8, (L) number of depleted cell types/segmentation states at GWAS p-value threshold 10-8, (M) 
number of independent SNPs at GWAS p-value threshold 10-5, (N) number of enriched cell types in open 
chromatin marks at GWAS p-value threshold 10-5, (O) number of conditionally independent cell types in open 
chromatin marks at GWAS p-value threshold 10-5, (P) number of enriched cell types in H3K27ac at GWAS p-
value threshold 10-5, (Q) number of enriched cell types in H3K4me3 at GWAS p-value threshold 10-5, (R) 
number of enriched cell types/segmentation states at GWAS p-value threshold 10-5, (S) number of depleted 
cell types/segmentation states at GWAS p-value threshold 10-5, (T) Tissues showing the largest enrichment in 
open chromatin states per trait category, (U) Tissues/histone modifications showing the largest enrichment 
per trait category, (V) Tissues/segmentation states showing the largest enrichment per trait category. Total 
number of GWAS variants (n) per trait can be found in Supplementary Table 3. 
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DHSs Histone Modifications Segmentations 
Anthropometric 
1 Body mass index BMI  50,166  16 0 - 0 1 14 0 62 0 - 0 0 14 0 
foetal_muscle*  Connective/epithelial/bone 
active enhancers, 
tissues including 
adipose and skeletal 
muscle*  
1 Height HGT  49,909  114 364 7 65 106 297 0 290 395 10 88 124 806 28 
1 
Waist hip ratio 
adjusted for BMI 
WHR  50,500  7 0 - 0 0 0 0 34 19 2 2 0 27 0 
Glycaemic 
2 
2hr Glucose adjusted 
for BMI 
2hrG  46,691  1 0 - 0 0 0 0 11 0 - 0 0 1 0 
blood and 
foetal 
intestine 
foetal intestine, spleen, 
adipose, pancreas 
poised promoters in 
pancreatic islets and 
stomach mucosa, 
active enhancers in 
pancreatic islets and 
transcription 
regulation in blood 
2 HbA1C HbA1C  52,079  8 0 - 0 0 0 0 45 2 2 7 0 2 0 
2 Fasting Proinsulin FPI  56,429  10 0 - 0 0 22 0 30 1 1 1 0 0 5 
2 Fasting Glucose FG  51,578  13 0 - 0 0 0 0 43 11 3 1 2 7 0 
2 Fasting Insulin FI  50,132  0 0 - 0 0 0 0 12 0 - 1 0 0 0 
2 Type 2 Diabetes T2D  47,928  10 0 - 0 0 1 0 65 5 3 3 5 3 0 
2 HOMA-IR HOMA-IR  49,450  0 0 - 0 0 0 0 14 0 - 0 0 1 0 
2 HOMA-B HOMA-B  49,249  4 0 - 0 0 0 0 20 0 - 0 0 2 0 
Blood pressure 
3 
Diastolic blood 
pressure 
DBP  52,446  7 0 - 0 0 0 0 43 0 - 1 0 2 0 
lung left ventricle 
transcription 
enhancers in blood 
and left ventricle 3 
Systolic blood 
pressure 
SBP  52,592  7 0 - 0 0 4 0 48 1 1 3 0 9 0 
Lipids 
4 
High-density 
lipoprotein 
HDL  61,981  66 88 3 22 6 135 26 150 154 3 65 35 483 119 
several (liver, 
blood, foetal 
intestine, 
colon, foetal 
thymus) 
liver, blood, 
gastrointestinal and 
adipose 
active enhancers in 
liver, transcription 
enhancers in foetal 
intestine and blood 
4 Total cholesterol TC  62,029  64 0 - 2 1 8 6 131 15 3 20 16 122 14 
4 Triglyceride TG  61,999  36 12 2 6 1 2 0 95 43 3 29 32 41 0 
4 
Low-density 
lipoprotein 
LDL  61,933  49 1 1 7 6 12 2 115 75 3 25 23 45 27 
Haematological 
5 Haemoglobin count HGB  49,658  21 11 3 10 2 141 0 84 20 3 15 4 97 0 
blood HSC/Blood/Immune 
transcriptional 
regulation and active 
enhancers in blood 
5 
Mean corpuscular 
volume 
MCV  49,387  45 167 8 71 103 187 0 132 247 5 87 120 831 1 
5 Red blood cell count RBC  49,414  25 12 2 9 2 11 0 103 91 4 47 35 357 0 
5 
Mean corpuscular 
haemoglobin 
concentration 
MCHC  49,466  13 0 - 2 0 3 0 45 6 2 3 0 10 0 
5 
Mean corpuscular 
haemoglobin 
MCH  49,239  39 129 5 54 106 134 0 116 200 5 72 122 323 0 
5 Packed cell volume PCV  49,236  16 3 2 2 0 31 0 63 69 4 47 40 254 0 
5 Mean platelet volume MPV  56,683  27 6 2 3 1 4 0 76 18 3 17 3 37 1 
5 Platelet count PLT  58,181  35 10 2 15 9 19 0 111 66 4 74 95 352 2 
Autoimmune 
disease 
6 Crohn's Disease CD  347,359  65 183 4 28 35 54 22 215 187 5 40 67 221 28 blood, foetal 
intestine, 
foetal thymus 
blood immune and 
gastrointestinal cells 
active enhancers in 
blood immune cells 
and thymus 6 Ulcerative colitis UC  356,248  67 27 2 13 11 49 3 218 150 3 39 45 183 22 
6 
Inflammatory Bowel 
Disease 
IBD 393,352 94 164 4 35 17 155 15 283 168 7 40 37 263 38   
Psychiatric disorder 7 Schizophrenia SCZ  170,825  117 4 1 17 15 98 0 619 2 2 8 1 29 6 
blood, foetal 
brain 
CNS and HSC/Blood/ 
Immune 
transcription/bivalent 
promoters in foetal 
brain 
Features = Total independent SNPs significant in GWAS for a given T * excluding height 
 
 
  
Total number of GWAS variants (n) per trait can be found in Supplementary Table 3. 
Online Methods 
  
Association Summary Statistics Data 
GWAS summary statistics from the analysis of 29 disease and quantitative phenotypes were obtained from a 
number of sources (see URLs). From GIANT we downloaded large studies on BMI 21, Height 22 and Waist hip 
ratio adjusted for BMI 23. From MAGIC we downloaded data on BMI adjusted 2hr glucose 24, HOMA B, HOMA 
IR, Fasting glucose, Fasting insulin 25, Fasting proinsulin 26 and HbA1C 27. Global lipid GWAS summary statistics 
for LDL, HDL, TC and TG we obtained from 28. Crohn’s disease, Ulcerative colitis and Inflammatory Bowel 
Disease 29 data was obtained from IIBDGC. SBP and DBP 30 data was downloaded ICBP. Type 2 diabetes 31 
GWAS summary statistics were downloaded from DIAGRAM. Schizophrenia data from 32 was further obtained 
and analysed. Blood trait data on HGB, MCH, MCV, MCHC, RBC and PCV was additionally obtained from the 
authors of van der Harst et al 33 and MPV and PLT data from the authors of Gieger et. al. 34 (Supplementary 
Table 3).  
  
DHS data 
DNaseI hypersensitive sites (hotspots) were obtained from ENCODE and the NIH Roadmap Epigenomics 
Mapping (see URLs) on all available cell types. DHS data was processed following DHSs data processing 
protocol described in an ENCODE study 4. Further information on the data can be found in Supplementary 
Table 2. 
 
H3K27ac and H3K4me3 data 
Processed NarrowPeak consolidated epigenome data was downloaded from the Roadmap Epigenomics portal 
(see URLs) for all available cell types for H3K27ac and H3K4me3 marks (98 and 127 cell types, respectively). 
Cell line information can be found in Supplementary Tables 7.  
  
Epigenome segmentation data 
Data from a chromatin state model with 25 states based on imputed data for 12 marks (H3K4me1, H3K4me2, 
H3K4me3, H3K9ac, H3K27ac, H4K20me1, H3K79me2, H3K36me3, H3K9me3, H3K27me3, H2A.Z, and DNase) 
across 111 Roadmap Epigenomics 15 and 16 ENCODE reference epigenomes was downloaded from the 
Roadmap Epigenomics portal (see URLs). State and cell line information can be found in Supplementary Tables 
9 and 7. 
  
LD data 
LD information (proxies) was calculated using PLINK 35 (v1.7) and the --tag-r2 0.01 --tag-kb 500 (and --tag-r2 0.8 
--tag-kb 500) flags in order to find all proxies within a 1Mb window around each variant at R-squared 
thresholds of 0.01 and 0.8. We computed these from the UK10K 36 sequence data on 3621 samples from two 
population cohorts (TwinsUK and ALSPAC) (data described elsewhere 36). Variants that were not observed in 
the UK10K data were excluded from our analysis. 
  
Data processing 
Given a genome-wide distribution of p-values for association with a given disease or quantitative trait, we 
perform the following pre-processing steps in order to calculate the level of enrichment and its significance for 
an annotation of interest. To remove possible biases due to linkage disequilibrium (LD) or dependence 
between variants we compute the r2 between all SNPs within 1-Mb windows and consider r2 of less than 0.01 
between two variants to mean (approximate) independence. Next, from the full set of genetic variants for 
each phenotype, we create an independent set of SNPs where in order to keep all possible GWAS signals we 
sequentially find and retain the next most significant (lowest P-value) variant independent of all other variants 
in our independence set. After LD pruning an average of 2.2% (with range 1.9-3.4%) of genome-wide variants 
remained in our independence set for enrichment analysis (Supplementary Table 3). Next, we annotate each 
independent SNP and consider it as overlapping a functional element if (i) the SNP itself resides in such a 
genomic region or (ii) at least one of its proxies in LD (r2 ≥ 0.8) and within 500 Kb with it does. We include the 
latter as the association of a SNP in GWAS potentially tags the effect of other variants, which could underlie 
the observed association signal. The advantage of our greedy pruning over a P-value independent pruning is 
that we retain larger proportion of potentially causal variants (or tags of such SNPs). This is particularly 
advantageous for GWA studies with low power and more pronounced at more stringent pruning thresholds. 
  
Quantifying enrichment and statistical significance 
To find the enrichment of GWAS signals within a given functional annotation at a genome-wide significance P-
value threshold T, we use the following logistic regression model  
logit E(y)=1α+XTSSβTSS+XTAGSβTAGS+XAjβAj 
where yi = 1 if SNP i has GWAS P-value < T, and yi = 0 otherwise. 1 denotes an intercept term (a vector of 1’s) 
and XAj denotes a binary annotation covariate for annotation j. XTSS and XTAGS are categorical covariates 
denoting which quantile bin of distance to nearest TSS and number of LD proxies (r2≥0.8) a variant falls in (by 
default we use 5 quantiles for TSS distance and 15 for number of LD proxies). These terms are added to 
account for possible biases in the analysis due to the GWAS P-value distribution correlating to them, which 
may also non-randomly associate with functional data. Due to the discreteness of the number of proxies and 
the skewness of their distribution in the pruned data, exact quantile binning is not always possible, in which 
case we create a stepwise binning in which we iteratively find the first (Q-q)’th quantile from the remaining 
variants after having already created q (out of Q) bins and removed those variants from consideration. We 
calculate ORs and test for their significance at T=10-1, 10-2, …, 10-8 for all traits at each given threshold. 
 
Testing for significant association between an annotation and GWAS SNP status means testing for βAj=0 vs 
βAj∈ℜ. If, additionally, βAj>0, this denotes enrichment, otherwise we consider it to be a depletion. OR statistic 
is then calculated via the following equation βAj=log ORAj. 
 
Model selection for multiple annotations is done by (i) sorting annotations in order of significance from single 
annotation model; (ii) iteratively trying to add an annotation to the model if it significantly improved the model 
fit (p<0.05) given all other annotations in the model using the following model: 
logit E(y)=1α+XTSSβTSS+XTAGSβTAGS+XA1βA1+…+ XAjβAj 
And (iii) reporting the final model and tree or retained/discarded annotations. 
 
Multiple testing 
To account for multiple testing in the number of annotations used, we apply a Bonferroni correction for the 
number of independent tests carried out. Due to the nature of the data, annotations need not be (and are not 
in general) independent (e.g. biological replicates of the same cell types). Thus, correcting for all annotations 
by assuming independence would be extremely stringent in practice. Instead, we estimate the effective 
number of independent tests performed similarly to Galwey, 2009 17. More specifically, we take an 
independent subsample of SNPs and find the eigenvalues of the correlation matrix between all considered 
annotations and then find the effective number of independent test from equation 16 in Galwey, 2009. This 
results in at most 194 independent annotations out of a total of 424 for the DHS data (for the 29 phenotypes 
considered), to which we apply Bonferroni correction (p~2.6x10-4). Further details can be found in the 
Supplementary Note. Similarly, for the segmentation data a total of 25x127=3175 annotations were used, 
which resulted in p~3.3x10-5 after correcting for multiple testing on the effective number of independent 
annotations at the 5% significance level. Finally, for the histone modification data we used a threshold of p~4.7 
× 10-4. 
  
False positive rate 
To get an estimate of GARFIELD’s false positive rate, we simulated 1000 random annotations by mimicking the 
peak lengths and between peak distances from the ENCODE HepG2 DHS cell line. We then performed 
enrichment analysis for each annotation-trait pair from the 1,000 simulated annotations and 29 publicly 
available disease or quantitative trait GWAS studies. We estimated the false positive rate as the proportion of 
cell types showing significant enrichment for a given trait and further compared GARFIELD to each of six other 
tools for a subset of 21 of the traits with the necessary summary statistics for running all other approaches. 
 
Analysis with other software 
For the method comparison analysis, we used threshold of T<10-8 for GARFIELD, GREGOR and GoShifter and no 
threshold for fgwas and LDSC. Enrichment was defined as p<2.6x10-4 and an effect with positive direction 
(ORGARFIELD>1, EnrichmentLDSC>1, Estimatefgwas>1; GREGOR and GoShifter only test for enrichment and not for 
depletion so they were used without this constraint). 
 
fgwas 
We used full GWAS summary statistics (no LD pruning or tagging) against each annotation at a time as 
recommended by the fgwas user manual. Enrichment was defined by p-value<0.05 for the false positive rate 
estimation and p-value<2.6x10-4 for the real data analysis to correct for multiple testing. 
 
LD-score regression (LDSC) 
For each annotation we prepared .ldscore files. Then for each annotation/trait pair we run LD-score regression 
accounting for the baseline model. We obtained enrichment p-values based on the resulting regression 
coefficients as per the software documentation. Analysis was restricted to hapmap3 SNPs again as per the user 
manual recommendation. Enrichment was defined by p-value<0.05 for the false positive rate estimation and p-
value<2.6x10-4 for the real data analysis to correct for multiple testing. 
  
GoShifter 
We restricted the variants to those from the 1000 genomes project due to LD tagging in GoShifter using the 
same panel. For each study, we selected variants with GWAS P-value less than 10-8 and pruned them similarly 
to GARFIELD according to LD r2≥0.01. Testing was done using r2≥0.8 for LD tagging and 10,000 permutations. 
Enrichment was defined by p-value<0.05 for the false positive rate estimation and p-value < 2.6 × 10-4 for the 
real data analysis to correct for multiple testing. The p-value of enrichment was calculated as the proportion of 
permutations producing at least as extreme overlap as the observed SNP-annotation overlap. 
 
GREGOR 
We restricted the variants to those from the 1000 genomes project due to LD tagging in GREGOR using the 
same panel. For each study, we selected variants with GWAS P-value less than 10-8 and pruned them similarly 
to GARFIELD according to LD r2≥0.01. Testing was done using r2≥0.8 and 500 minimum neighbouring SNPs for 
each tested variant. Enrichment was defined by p-value<0.05 for the false positive rate estimation and p-
value<2.6x10-4 for the real data analysis to correct for multiple testing. 
 
GPA 
We used full GWAS summary statistics, with no LD pruning or tagging and used a maximum of 10,000 EM 
iterations. Enrichment was defined by p-value<0.05 and q1>q0 for the false positive rate estimation. 
 
CPU time estimates 
We compared total CPU usage times between different methods for the analyses of 21 traits and 424 
annotations and the respective average CPU times for a single trait/annotation pair. Analyses for each 
trait/annotation were run separately (whenever possible) on a compute cluster containing machines with the 
following architecture: Linux (x86-64) and 2x2.1 Ghz 16 core AMD 6378. Then cumulative run time over all 
traits/annotations and average run time for a single trait/annotation pair was reported (Supplementary Table 
6). 
 
Segmentation OR distribution and between trait sharing 
From all significantly enriched cell types per trait and segmentation state, we calculated the median OR and 
then plotted its distribution (on a log scale) across traits in order to estimate the per-state OR. Additionally, we 
took all significantly enriched cell types for pairs of annotations in order to remove the effect of power for 
annotation density and looked at the distribution of ORs for enhancer and promoter states versus those of 
transcription states. Finally, we counted the number of cell types per feature that were found to be 
significantly enriched (or depleted) in a single trait or shared between multiple traits. 
  
Software 
GARFIELD is available as a standalone tool and an R-package (see URLs). The tool consists of two main parts: (i) 
pruning and annotation of the GWA study of interest and (ii) calculating odds ratios and significance of the 
observed enrichment. Additionally, we provide scripts for further prioritization of annotations by iteratively 
adding annotations in a joint model if they improve the model fit (Chi-squared test). 
 
Reporting Summary 
Further information on research design in available in the Life Sciences Reporting Summary linked to this 
article. 
 
Data availability 
Web links for publicly available GWAS datasets and regulatory information databases are included in URLs 
section. Restriction of availability apply to blood cell indices GWASs from van der Harst et al. 33  and Gieger et 
al. 34, which have been obtained through the manuscripts authors. Any other data that supports the findings of 
this study is available from the corresponding author upon request. 
 
Code availability 
Custom code can be found at http://www.ebi.ac.uk/birney-srv/GARFIELD/ 
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Editorial summary:  
GARFIELD is a new approach that classifies genomic features related to phenotypes based on 
integrating GWAS signals with functional annotations. GARFIELD is used to characterize 
enrichment patterns for 29 traits integrated with ENCODE and Roadmap Epigenomics annotations.  
